CM Yogi Announces UP's First Pharma Park in Lalitpur
Synopsis
Uttar Pradesh Chief Minister Yogi Adityanath has announced that the state's first Pharma Park is being developed in Lalitpur, with a dedicated AYUSH Pharma Park to be built subsequently, advancing UP's pharmaceutical manufacturing ambitions under the Atmanirbhar Bharat framework.
Key Takeaways
Uttar Pradesh's first dedicated Pharma Park is being developed in Lalitpur district.
CM Yogi Adityanath announced a second, separate Pharma Park exclusively for AYUSH will be built after the Lalitpur park.
The move aligns with the Government of India's Bulk Drug Parks scheme launched in 2020 to boost domestic API manufacturing.
UP's Industrial Investment and Employment Promotion Policy 2022 had identified pharma and AYUSH clusters as priority sectors.
The Lalitpur park targets Bundelkhand , a sub-region historically underserved by industrial investment.
Both parks align with the national Atmanirbhar Bharat goal of reducing India's dependence on imported pharmaceuticals.
The Chief Minister's Office of Uttar Pradesh announced on Saturday, 20 June 2026 that Uttar Pradesh's first dedicated Pharma Park is being developed in Lalitpur, with Chief Minister Yogi Adityanath adding that a separate Pharma Park exclusively for AYUSH will follow.
Context
Sharing the update in Hindi, CM Yogi Adityanath stated: 'Lalitpur mein Uttar Pradesh ka pehla Pharma Park viksit kiya ja raha hai' ('Uttar Pradesh's first Pharma Park is being developed in Lalitpur'). He added that after this, the state will build a separate Pharma Park for AYUSH — the government's umbrella framework covering Ayurveda, Yoga, Unani, Siddha, and Homeopathy. The announcement signals a two-track approach: one park for conventional pharmaceuticals and a second dedicated to traditional medicine manufacturing.
Policy Backdrop
The Lalitpur Pharma Park fits within a layered national and state policy framework. In 2020, the Government of India launched the Bulk Drug Parks scheme to boost domestic Active Pharmaceutical Ingredient (API) manufacturing and reduce dependence on imports. Uttar Pradesh's Industrial Investment and Employment Promotion Policy 2022 subsequently identified pharma and AYUSH clusters as priority sectors for targeted infrastructure investment.
The broader drive aligns with the Atmanirbhar Bharat agenda, under which multiple states have announced sector-specific industrial parks since 2021 to capture supply-chain shifts accelerated by the pandemic. Uttar Pradesh has pursued this model across sectors, positioning dedicated parks as instruments to attract large-scale manufacturing investment.
Stakeholders and Impact
The primary beneficiaries of the Lalitpur Pharma Park are pharmaceutical manufacturers seeking plug-and-play industrial infrastructure, as well as the local workforce in Lalitpur district — a region in the Bundelkhand sub-region of Uttar Pradesh that has historically lagged in industrial development. A dedicated AYUSH Pharma Park, once operationalised, would open a separate investment corridor for companies producing herbal, homeopathic, and traditional medicine products — a fast-growing segment of India's health economy.
Pharma companies, bulk drug manufacturers, AYUSH product firms, and ancillary logistics and packaging businesses stand to benefit from the specialised infrastructure. For the state government, the parks represent a bid to diversify Uttar Pradesh's industrial base beyond its traditional strengths in agro-processing and textiles.
What's Next
Observers will watch for formal land acquisition updates, first-phase investment commitments, and any Request for Proposal (RFP) or site notifications tied to the Lalitpur park. The proposed AYUSH Pharma Park — described by CM Yogi as a follow-on project — is likely to surface in upcoming state budget announcements or investor summit cycles. The sequencing of both parks will be a key indicator of the state's execution pace on its pharma industrial ambitions.
Point of View
One for AYUSH — reflects a deliberate political economy logic: it lets the Yogi government court both mainstream pharmaceutical capital and the fast-growing traditional medicine industry simultaneously. Lalitpur's selection is also notable as a signal to the Bundelkhand region, which has long demanded industrial attention. The sequencing of the AYUSH park as a follow-on, rather than a concurrent project, suggests the government is pacing its commitments carefully, likely awaiting investor response to the Lalitpur park before locking in a second site. Taken together, the announcements extend UP's pattern of using sector-specific industrial parks as the primary vehicle for manufacturing-led growth.
NationPress
20 Jun 2026
Frequently Asked Questions
Where is Uttar Pradesh's first Pharma Park being built?
Uttar Pradesh's first Pharma Park is being developed in Lalitpur district, as announced by Chief Minister Yogi Adityanath on 20 June 2026.
What is the AYUSH Pharma Park announced by CM Yogi?
CM Yogi Adityanath announced a separate, dedicated Pharma Park for AYUSH — covering Ayurveda, Yoga, Unani, Siddha, and Homeopathy manufacturing — to be built after the Lalitpur park is established.
What is the Bulk Drug Parks scheme and how does it relate to UP's Pharma Park?
The Bulk Drug Parks scheme was launched by the Government of India in 2020 to promote domestic Active Pharmaceutical Ingredient manufacturing. UP's Lalitpur Pharma Park aligns with this national initiative to reduce import dependence in pharmaceuticals.
Why was Lalitpur chosen for UP's first Pharma Park?
Lalitpur lies in the Bundelkhand sub-region, which has historically seen limited industrial investment. Its selection signals the state government's intent to channel pharma-sector growth into underserved districts.
How does the UP Pharma Park fit into the Atmanirbhar Bharat initiative?
The Lalitpur Pharma Park and the proposed AYUSH park both support the Atmanirbhar Bharat goal of building self-reliant domestic manufacturing capacity in pharmaceuticals and traditional medicine, reducing India's reliance on imported drugs and APIs.
